Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
✍ Scribed by Veeck, J; Niederacher, D; An, H; Klopocki, E; Wiesmann, F; Betz, B; Galm, O; Camara, O; Dürst, M; Kristiansen, G
- Book ID
- 110070407
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 229 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0950-9232
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The methylation status of cystatin M (__CST6__) gene in breast tumors was investigated and its prognostic significance as a novel breast cancer biomarker was evaluated. Using methylation‐specific PCR (MSP), __CST6__ promoter methylation was examined in 134 formalin fixed paraffin‐embedd
## Abstract ## BACKGROUND: Abnormal activation of the Wnt/β‐catenin signaling pathway is common and critical in the pathogenesis of digestive cancers. In this study, the authors investigated the promoter methylation of the dickkopf homolog 3 gene __Dkk‐3__ in these cancers and its prognostic signi
## Abstract Recently, we analysed the 8p11‐12 genomic region for copy number and gene expression changes in a panel of human breast cancer cell lines and primary specimens. We found that __SFRP1__ (Secreted frizzled related protein 1) is frequently under expressed even in breast tumours with copy n